Associated Papers
Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.
Stein CM et al.
Leukemia, 2026
Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts.
Eldomery MK et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer.
Vlachavas EI et al.
Molecular Oncology, 2025
A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays.
Galbo PM et al.
The Journal of Molecular Diagnostics : Jmd, 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting.
Wallen ZD et al.
Frontiers in Genetics, 2025
Case Report: Novel truncating PPM1D variant in a dichorionic diamniotic (DCDA) twin with Jansen-de Vries syndrome. an updated perspective.
Merida De la Torre FJ et al.
Frontiers in Genetics, 2025
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM et al.
Leukemia, 2024
Clonal evolution of hematopoietic stem cells after cancer chemotherapy.
Uryu H et al.
Biorxiv : the Preprint Server for Biology, 2024
Genotype-to-phenotype mapping of somatic clonal mosaicism via single-cell co-capture of DNA mutations and mRNA transcripts.
Yuan DJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G et al.
Scientific Reports, 2023
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques.
von Scheidt M et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
A Case Study on PPM1D and 9 Other Shared Germline Alterations in a Family.
Biswas S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
Increased clonal hematopoiesis involving DNA damage response genes in patients undergoing lung transplantation.
Tague LK et al.
Jci Insight, 2023
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
Kar SP et al.
Nature Genetics, 2022
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
Svensson EC et al.
Jama Cardiology, 2022
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka P et al.
Nature Communications, 2022
Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
Kazarian E et al.
Scientific Reports, 2021
Inherited causes of clonal haematopoiesis in 97,691 whole genomes.
Bick AG et al.
Nature, 2020
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Burocziova M et al.
Cell Death & Disease, 2019
Clinical utility of custom-designed NGS panel testing in pediatric tumors.
Surrey LF et al.
Genome Medicine, 2019
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.
Lei K et al.
Scientific Reports, 2018
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Pharoah PDP et al.
Journal of the National Cancer Institute, 2016
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A et al.
Molecular Cancer Therapeutics, 2016
PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M et al.
Oncogene, 2015
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y et al.
Bioorganic & Medicinal Chemistry Letters, 2014
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L et al.
Nature Genetics, 2014
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Akbari MR et al.
Journal of the National Cancer Institute, 2014
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P et al.
The Journal of Cell Biology, 2013